MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-13-2025
DURECT Corporation Total Current Liabilities 2011-2026 | DRRX
Annual Total Current Liabilities DURECT Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 M | 34 M | 10.1 M | 10.7 M | 36.8 M | 7.66 M | 15.8 M | 28.8 M | 7.45 M | 6.97 M | 7.18 M | 6.93 M | 14.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.8 M | 6.93 M | 16.5 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M |  USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.2 | 0.42 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 12.84 | 2.8 % | $ 657 M | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | $ 21.5 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
63 M | $ 6.03 | -10.27 % | $ 374 M | USA |
 |
Harrow Health
HROW
|
49.3 M | $ 54.06 | 8.3 % | $ 1.76 B | USA |
 |
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
5.02 M | $ 1.23 | 1.65 % | $ 21.5 M |  China |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 7.51 | 4.16 % | $ 2.74 B | Canada |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.95 | -0.77 % | $ 55.5 M | USA |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 4.36 | -5.93 % | $ 574 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 25.21 | 3.07 % | $ 1.17 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 3.73 | 2.46 % | $ 4.63 M | USA |
 |
Rockwell Medical
RMTI
|
16.6 M | $ 0.98 | 13.92 % | $ 22.9 M | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
1.04 B | $ 14.36 | 3.42 % | $ 1.97 B | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
11.9 M | $ 2.28 | 0.58 % | $ 308 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 1.11 | -4.31 % | $ 4.79 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.11 | -6.06 % | $ 124 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
93.4 M | $ 9.62 | 5.25 % | $ 683 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
30.3 M | $ 5.33 | -2.14 % | $ 218 M | USA |
 |
SCYNEXIS
SCYX
|
16.3 M | $ 0.64 | -0.03 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
433 M | $ 9.43 | -3.03 % | $ 5.83 B | Canada |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 1.79 | 8.78 % | $ 18.7 M | USA |
 |
Zomedica Corp.
ZOM
|
9.03 M | - | -0.21 % | $ 98 M | USA |